echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Initiation of triple immunization program for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin...

    Initiation of triple immunization program for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin...

    • Last Update: 2021-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Transfer from Pharmaceutical Mission Hills

    On June 4th, Wanchun Medicine announced that a Phase 1b/2 study of pranabulin combined with checkpoint inhibitors and radiotherapy at MD Anderson Cancer Center ushered in the first patient administration.


    It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex.


    Pranabrin is a selective immunomodulator that binds to microtubules.


    Wanchun Medicine demonstrated the concept of triple therapy at the AACR annual meeting held in 2020.


    Effectiveness study: In an animal model of breast cancer that is resistant to PD-1 antibody monotherapy, the triple I/O treatment program of Pranabrin+PD-1 antibody+radiotherapy achieved 100% complete tumor remission (CR).


    Distal effect: When the anticancer effect of pranabulin triple therapy on chemotherapy-irradiated and unirradiated tumors (distal effect) was evaluated in the same mouse, the results showed a good distal effect, indicating that the systemic anticancer effect was activated.


    This provides data support for the concept of triple therapy and clinical research.


    Therefore, the goal of this trial is to allow those patients who developed drug resistance during PD-1/PD-L1 treatment to continue to receive the original immunotherapy, and to reverse their resistance to the original PD-1/PD-L1 through triple therapy.


    Public information shows that Panabrin has completed 9 clinical trials around the world, including four phase 2 and 3 international multicenter clinical trials for neutropenia (CIN), and submitted them in China and the United States.


    Note: The original text has been deleted

    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.